Nureca Ltd
Incorporated in 2016, Nureca Ltd is in the business of Home Healthcare and Wellness Products.[1]
- Market Cap ₹ 330 Cr.
- Current Price ₹ 346
- High / Low ₹ 358 / 200
- Stock P/E 152
- Book Value ₹ 186
- Dividend Yield 0.00 %
- ROCE 2.07 %
- ROE 0.16 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- The company has delivered a poor sales growth of -7.15% over past five years.
- Company has a low return on equity of -0.51% over last 3 years.
- Earnings include an other income of Rs.7.65 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 5m | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0 | 1 | 1 | 99 | 213 | 256 | 112 | 95 | 115 | 147 | 153 | |
| 0 | 1 | 1 | 90 | 152 | 200 | 127 | 106 | 124 | 150 | 152 | |
| Operating Profit | 0 | 0 | 0 | 10 | 62 | 56 | -15 | -11 | -10 | -3 | 1 |
| OPM % | 0.0% | 3.4% | 4.1% | 10% | 29% | 22% | -14% | -12% | -8% | -1.8% | 0.6% |
| 0 | 0 | 0 | 0 | 3 | 8 | 7 | 11 | 13 | 8 | 8 | |
| Interest | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 0 | 0 | 0 | 9 | 62 | 61 | -11 | -3 | -0 | 3 | 6 |
| Tax % | 50% | 33% | 26% | 26% | 26% | -23% | -25% | 46% | 90% | ||
| 0 | 0 | 0 | 6 | 47 | 45 | -8 | -2 | -1 | 0 | 2 | |
| EPS in Rs | 0.00 | 20.00 | 20.00 | 6,410.00 | 46.53 | 45.31 | -8.42 | -2.44 | -0.67 | 0.31 | 2.13 |
| Dividend Payout % | 0% | 0% | 0% | 4% | 7% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -7% |
| 3 Years: | 10% |
| TTM: | 22% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -64% |
| 3 Years: | 27% |
| TTM: | 264% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -26% |
| 3 Years: | 2% |
| 1 Year: | 49% |
| Return on Equity | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 4% |
| 3 Years: | -1% |
| Last Year: | 0% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 0.01 | 0.01 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 0 | 0 | 0 | 15 | 153 | 194 | 185 | 183 | 182 | 168 |
| 0 | 0 | 0 | 10 | 4 | 4 | 3 | 2 | 4 | 2 | |
| 0 | 0 | 1 | 9 | 19 | 11 | 8 | 9 | 10 | 14 | |
| Total Liabilities | 0 | 0 | 1 | 34 | 186 | 220 | 207 | 204 | 206 | 194 |
| 0 | 0 | 0 | 1 | 3 | 10 | 8 | 6 | 8 | 12 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 1 | 34 | 62 | 97 | 4 | 4 |
| 0 | 0 | 1 | 33 | 181 | 175 | 136 | 101 | 194 | 177 | |
| Total Assets | 0 | 0 | 1 | 34 | 186 | 220 | 207 | 204 | 206 | 194 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0 | -8 | 35 | 2 | 12 | -3 | -19 | 0 | |||
| 0 | -0 | -110 | -3 | -18 | 18 | 9 | 16 | |||
| 0 | 8 | 92 | -7 | -2 | -1 | -1 | -19 | |||
| Net Cash Flow | 0 | -0 | 17 | -9 | -8 | 14 | -11 | -2 | ||
| Free Cash Flow | -0 | -8 | 35 | -4 | 12 | -4 | -23 | -5 | ||
| CFO/OP | -81% | 81% | 35% | -107% | 40% | 183% | 4% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 365 | 87 | 65 | 47 | 0 | 4 | 14 | 7 | 14 | 24 |
| Inventory Days | 0 | 101 | 590 | 93 | 135 | 174 | 154 | 156 | 163 | 162 |
| Days Payable | 233 | 849 | 33 | 32 | 13 | 23 | 27 | 26 | 23 | |
| Cash Conversion Cycle | 365 | -45 | -195 | 107 | 103 | 165 | 145 | 136 | 151 | 164 |
| Working Capital Days | 182 | -12 | -45 | 85 | 61 | 109 | 148 | 160 | 145 | 132 |
| ROCE % | 100% | 75% | 76% | 67% | 33% | -5% | -1% | 0% | 2% |
Insights
In beta| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cumulative Online Customer Base thousands |
|
||||||
| Live Distributors count |
|||||||
| Online Revenue Contribution % |
|||||||
| Active SKUs count |
|||||||
| Dr Trust 360 App Users millions |
|||||||
| Live States & Union Territories count |
|||||||
| Manufacturing Subsidiary (NTPL) Sales INR Crore |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Disclosure Under Regulation 7(2) Of SEBI (Prohibition Of Insider Trading) Regulations, 2015 ( PIT Regulations ).
- Manual Regulation 7(2) disclosure for designated person's share purchase; system-driven filing pending.
-
Additional Details Required For Corporate Announcement Under Regulation 30(4) Of The SEBI (LODR) Regulations, 2015.
- Nureca disclosed CGST rectification settlement via ITC reversal of Rs. 15.40 lakh for FY 2021-22.
-
Pendency Of Litigation(S)/Dispute(S) Or The Outcome Impacting The Company.
- Nureca received GST rectification order for 2021-22, reversing ITC of Rs. 15.40 lakh with no further demand.
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
- Nureca held its 10th AGM on July 28, 2026; approved FY26 accounts and director reappointments.
Annual reports
Concalls
-
Jul 2026TranscriptAI SummaryPPT
-
May 2026TranscriptAI SummaryPPT
-
Jan 2026TranscriptAI SummaryPPT
-
Jan 2026TranscriptAI SummaryPPT
-
Oct 2025TranscriptAI SummaryPPT
-
Jul 2025TranscriptAI SummaryPPT
-
May 2025TranscriptAI SummaryPPT
-
Jan 2025TranscriptAI SummaryPPT
-
Oct 2024TranscriptAI SummaryPPT
-
Aug 2024TranscriptAI SummaryPPT
-
May 2024TranscriptAI SummaryPPT
-
Feb 2024TranscriptAI SummaryPPT
-
Nov 2023TranscriptAI SummaryPPT
-
Aug 2023TranscriptAI SummaryPPT
Business Overview:[1][2]
NL is a digitally first, consumer healthcare company with presence in categories such
as home diagnostics, wellness devices, and personal fitness equipment under brands like
Dr Trust and Dr Physio. The company has 277+ Active SKUs, and 7 New Products were launched during Q1FY26